Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression

This is a clinical practice guideline for premenopausal women with Stage I to III hormone receptor-positive breast cancer. The guideline reviews the use of ovarian suppression in addition to standard adjuvant or standard therapy, with recommendations stratified by risk. Outcomes of interest included survival (overall, disease free), freedom from breast cancer at 5 years, freedom from distant recurrence at 5 years, adverse events, quality of life, patient-reported outcomes, and cognitive impairment.